MAA Intelligence
Advancing Korean medical AI, together
The Medical AI Alliance connects biopharma, medical AI, devices and clinical networks. We publish 418 Korean listed medical companies and 42,000+ regulatory records in both Korean and English.
Healthcare innovation is fragmented. Collaboration is the missing layer.
Biopharma, AI, medical devices, and clinical institutions each hold critical pieces of the healthcare puzzle — but they rarely operate in a coordinated way. MAA exists to bridge that gap: providing a structured, governance-backed framework for organizations to collaborate, share capabilities, and build the future of medical AI together.
9
Alliance members spanning biopharma, AI, diagnostics, devices, security, and clinical networks
8
Members listed on the Korea Exchange, subject to public disclosure requirements
Multi-sector
Coverage across the full healthcare value chain, from R&D to clinical deployment
A strategic coordination layer for medical AI and healthcare.
MAA is not a product company. It is an alliance — a structured platform through which member organizations combine expertise, data capabilities, and industry networks to drive meaningful collaboration across the healthcare ecosystem.
Cross-sector membership
Formal alliance members include publicly listed leaders in biopharma, AI, diagnostics, patient monitoring, security infrastructure, and hospital networks.
Ecosystem governance
MAA provides the coordination structure — aligning interests, managing partnerships, and enabling responsible collaboration around healthcare data and technology.
Open to partners
Beyond formal membership, MAA works with startups, research institutions, hospitals, and government bodies as strategic partners in specific initiatives.
Nine organizations. One ecosystem.
MAA members represent the full healthcare value chain — from drug development and AI diagnostics to clinical infrastructure and digital trust.
Latest from the alliance.
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi Pharmaceutical licensed obesity drug HM17321 to Genentech (Roche) for up to $2.3B with $190M upfront; first-in-class UCN2 analog designed to reduce fat while preserving muscle mass.
Read original →Hanmi Pharm Signs Record $2.3B Exclusive Licensing Deal with Genentech for Novel Obesity Drug HM17321
Hanmi Pharmaceutical inked a $2.3B deal with Genentech for HM17321, a first-in-class UCN2 analog designed to reduce fat while preserving lean muscle mass; Genentech pays $190M upfront.
Read original →Hanmi Pharm Signs Exclusive $2.3B Licensing Deal with Genentech for Obesity Drug HM17321
Hanmi Pharmaceutical licensed muscle-sparing obesity candidate HM17321 to Genentech (Roche) for up to $2.3B, receiving $190M upfront; Genentech takes over from Phase 2.
Read original →Let your AI query this index directly
Connect this index to ChatGPT, Claude, Cursor or any MCP-capable tool, and your AI can look up company profiles, products, R&D, three years of financials, and regulatory and clinical records for 420 listed Korean medical companies as it answers. No download, no sign-up — paste one URL. Free and read-only.
https://medicalaialliance.org/api/mcpBuild the future of healthcare with us.
MAA welcomes organizations that are serious about healthcare innovation — whether as a formal member or as a strategic partner.